Schneider Petra, Bousema Teun, Omar Sabah, Gouagna Louis, Sawa Patrick, Schallig Henk, Sauerwein Robert
Radboud University Nijmegen Medical Centre, Medical Microbiology 268, P.O.Box 9101, 6500 HB, Nijmegen, The Netherlands.
Int J Parasitol. 2006 Apr;36(4):403-8. doi: 10.1016/j.ijpara.2006.01.002. Epub 2006 Jan 24.
The effects of drugs on Plasmodium falciparum transmission stages may reduce the spread of parasites in the population and contribute to malaria control. Detailed quantitative studies on (sub)microscopic gametocytaemia have become feasible with the availability of real-time Pfs25 quantitative Nucleic Acid Sequence-based Amplification (QT-NASBA), which can be used to detect gametocyte densities above 20 gametocytes per millilitre from in vitro cultures. Gametocyte dynamics were investigated in children with uncomplicated P. falciparum malaria after treatment with sulphadoxine-pyrimethamine (SP) or a combination of SP and artesunate (SP+AS), in a 28-days drug efficacy study. This study demonstrated that gametocyte prevalence in 873 samples from symptomatic Kenyan children was 2.8 times higher by QT-NASBA compared with microscopy. Microscopy-positive cases showed a significant correlation with QT-NASBA for gametocyte density. At enrolment, gametocyte prevalence was 86% by QT-NASBA compared with 22% by microscopy. Gametocytes were detected in 97% of children in at least one blood sample and in 38% of children in all samples obtained during the 28-days follow-up. Both the risk of gametocyte carriage and gametocyte density were considerably higher after treatment with SP compared with SP+AS. Gametocyte prevalence and density decreased with time in the SP+AS group, but not in the SP-treated children. Our data suggest that the potential of malaria transmission remains high even after treatment with artemisinin combination therapy, although prevalence and density of gametocytes is lower after SP+AS.
药物对恶性疟原虫传播阶段的影响可能会减少寄生虫在人群中的传播,并有助于疟疾控制。随着实时Pfs25定量核酸序列扩增技术(QT-NASBA)的出现,对(亚)显微配子体血症进行详细的定量研究变得可行,该技术可用于检测体外培养物中每毫升高于20个配子体的配子体密度。在一项为期28天的药物疗效研究中,对单纯性恶性疟原虫疟疾患儿在接受周效磺胺-乙胺嘧啶(SP)或SP与青蒿琥酯联合用药(SP+AS)治疗后的配子体动态进行了研究。这项研究表明,与显微镜检查相比,QT-NASBA检测到的873份有症状肯尼亚儿童样本中的配子体患病率高出2.8倍。显微镜检查呈阳性的病例与QT-NASBA检测的配子体密度显著相关。在入组时,QT-NASBA检测到的配子体患病率为86%,而显微镜检查为22%。在至少一份血样中,97%的儿童检测到配子体,在28天随访期间采集的所有样本中,38%的儿童检测到配子体。与SP+AS相比,SP治疗后配子体携带风险和配子体密度均显著更高。在SP+AS组中,配子体患病率和密度随时间下降,但在接受SP治疗的儿童中并非如此。我们的数据表明,即使在接受青蒿素联合疗法治疗后,疟疾传播的可能性仍然很高,尽管SP+AS治疗后配子体的患病率和密度较低。